INTERAKSI OBAT TERHADAP PERPANJANGAN INTERVAL QT

NAOMI FENTY NOVITA, DIKA PRAMITA DESTIANTY

Abstrak


ABSTRAK

Interval QT merupakan lamanya waktu yang dibutuhkan jantung untuk melakukan repolarisasi setelah terjadinya proses depolarisasi. Perpanjangan interval QT sendiri dapat menyebabkan aritmia dan dapat menyebabkan berhentinya kerja jantung secara mendadak. Interaksi dari obat-obatan merupakan alasan yang umum untuk perpanjangan interval QT. Faktor lain yang dapat mempengaruhi perpanjangan interval QT diantaranya  disfungsi hati dan ginjal,usia lanjut, jenis kelamin (wanita), genetik, ketidak seimbangan elektrolit, dan gangguan kardiovaskular. Beberapa cara penilaian interval QT  yaitu dengan pengukuran mesin EKG standar atau pengukuran interval QT secara manual. Dari beberapa sumber yang ditelaah berupa jurnal dan internet,  di dapatkan bahwa beberapa obat yang dapat meningkatkan resiko perpanjangan interval QT diantara lain adalah  Sparfloxacin & Terfenadine , Cefuroxime terhadap Propofol dan sevoflurane , Loratadine, Terfenadine & Nefazodone , Methadone & Buprenorphine , Droperidol & Ondansetron, Fluoroquinolone & Azole , Terfenadine & Ketoconazole , Domperidone & Ketoconazole, Umeclidinium & Vilanterol, Cisapride & Diltiazem, Itrakonazoe & Astemizole.

Kata kunci : Prolong QT ,Interaksi obat, , Aritmia.

ABSTRACK

The QT interval is the length of time it takes the heart to repolarize after the depolarization process. The extension of the QT interval itself can cause arrhythmias and can cause sudden cessation of the heart's work. The interaction of drugs is a common reason for the extension of the QT interval. Other factors that can affect the extension of the QT interval include liver and kidney dysfunction, old age, gender (female), genetics, electrolyte imbalance, and cardiovascular disorders. Some ways to assess the QT interval are by measuring a standard ECG machine or manually measuring the QT interval. From several sources reviewed in the form of journals and the internet, it was found that some drugs that can increase the risk of prolonging the QT interval include Sparfloxacin & Terfenadine, Cefuroxime against Propofol and sevoflurane, Loratadine, Terfenadine & Nefazodone, Methadone & Buprenorphine, Droperidol & Ondansetron, Fluoroquinolone & Azole, Terfenadine & Ketoconazole, Domperidone & Ketoconazole, Umeclidinium & Vilanterol, Cisapride & Diltiazem, Itrakonazoe & Astemizole.

.Keywords: Prolong QT,  Drug interactions, , Arrhythmias

Teks Lengkap:

PDF

Referensi


AA, P. P. (2014). The measurement of the QT interval. Curr Cardiol Rev , 10: 287–294.

AJ, M. M. (2001). Evaluation of druginduced QT interval prolongation: implications for drug approval and labelling. Drug Saf , 24: 323–351.

AJ, Malik M and Camm. (2001). Evaluation of druginduced QT interval prolongation: implications for drug approval and labelling. Drug Saf, 24: 323–351.

Al-Khatib SM, A. L. (2003). What clinicians should know about the QT interval. JAMA, 289:2120-2127.

Audra R. Thomas, P. L.-N. ( 1998 ). Prolongation of the QT Interval Related to Cisapride- Diltiazem Interaction . PHARMACOTHERAPY , 381-385.

Beny Charbit, M. J.-B. (2008). Droperidol and Ondansetron-induced QT Interval Prolongation. Anesthesiology, 109:206–12.

Darrell R. Abernethy, M. P. (2000). Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. CLINICAL PHARMACOLOGY & THERAPEUTICS , 96-103.

DM, R. (2008 ). Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm, 5(8): 1213–1215.

Drew BJ, A. M. (2010). on behalf of the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing and the American College of Cardiology Foundation. Prevention of torsades de pointes in hospital setting. Circulation, 121:1047-60.

Evandro Tinoco Mesquita, F. C. (1999). Effects of Propranolol on the QT Dispersion in Congestive Heart Failur. Arq Bras Cardiol, volume 73 (nº 3), 295-298.

Dávila 1, J. S. (2006). Effect of H1 antihistamines upon the cardiovascular system. J Investig Allergol Clin Immunol , Vol. 16, Supplement 1: 13-23.

Inc, A. ( 2017). Combined list of drugs that prolong QT and/or cause Torsades de Pointes (TdP). https://crediblemeds.org/pdftemp/ pdf/CombinedList.pdf. .

Inc, AZCERT. (2017). Combined list of drugs that prolong QT and/or cause Torsades de Pointes (TdP). https://crediblemeds.org/pdftemp/ pdf/CombinedList.pdf.

Isbister GK, C. L. (2009). Inter-rater reliability of manual QT measurement and prediction of abnormal QT,HR pairs. Clin Toxicol (Phila) , 47:884–888.

Isbister GK, P. C. ( 2013). Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. British journal of clinical pharmacology, 76(1):48-57.

John D. Zeuli, a. J. (2013). Effect of Combined Fluoroquinolone and Azole Use on QT Prolongation in Hematology Patients. Antimicrobial Agents and Chemotherapy p, 1121–1127.

Kasamaki Y, O. Y. ( 2011). Automated versus manual measurement of the QT interval and corrected QT interval. Ann Noninvasive Electrocardiol, 16:156–164.

Katinka Anchersen, T. C. (2009). Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment:a mortality assessment study. Addiction, Addiction, 104, 993–999.

Malcolm J. Boyce, K. J. (2011). Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, doubleblind, crossover study. British Journal of Clinical Pharmacology, 411–421 .

Malik M, C. A. (2001). Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf, 24:323–351.

Mohd. Akhtar, N. S. (2002). EFFECT OF SPARFLOXACIN AND TERFENADINE COMBINATION ON QT-INTERVALS AT VARIOUS RR-INTERVALS. Indian Journal of Pharmacology, 34: 264-268.

Nachimuthu S, A. M. (2012). Drug-induced QT interval prolongation: mechanisms and clinical management [internet]. Ther Adv Drug Saf, 3(5): 241 – 253. .

Peter K. Honig, M. M., Dale C. Wortham, M., Kaveh Zamani, P., & Dale P. Conner, P. (1993). Terfenadine-Ketoconazole Interaction Pharmacokinetic and Electrocardiographic Consequences. JAMA, 1513-1518.

Pickham D, H. E. (2012). High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study Critical Care Medicine. 2(40):394-9. .

Pickham, A. L. (2016). “Basic cardiac electrophysiology and common drug-induced arrhythmias,” . Critical Care Nursing ClinicsofNorthAmerica. , ,vol.28,no.3,pp.357–371.

Postema PG, D. J. ( 2008). Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm, 5:1015–1018.

Ramalho D, F. J. (2018). Drug-Induced Life-Threatening Arrhythmias and Sudden Cardiac Death: A Clinical Perspective of Long QT, Short QT and Brugada Syndrome. Rev Port Cardiol , 37: 435-446.

Romain A. Lefebvre, A. V. (1997). Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br J Clin Pharmacol, 319-322.

S, V. (2009). The QT interval: too long, too short or just right. Heart Rhythm , 6: 711–715.

Schwartz PJ, S. C. (2006). The Jervell and Lange-Nielsen Sundrome: natural history, molecular basis and clinical outcome. Circulation, 113:783-90.

Trinkley KE, P. I. (2013). QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin , 29:1719-26.

Wagg, R. M. (2016). Concentration-QT analysis of the randomized, placeboand moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. J Pharmacokinet Pharmacodyn , 43:153–164 .

Yanqiu Liu, H. G. (2019). A Comparison of the Effect of Sevoflurane and Propofol on Ventricular Repolarisation after Preoperative Cefuroxime Infusion. BioMed Research International, Volume 2019, Article ID 8978906, 6 pages.

Yap YG, C. A. (2003). Drug induced QT prolongation and torsades de pointes. Heart, 89:1363-1372.




DOI: https://doi.org/10.24198/jf.v18i1.23138

DOI (PDF): https://doi.org/10.24198/jf.v18i1.23138.g12650

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved